

# UniQure NV (QURE) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/UCCA23FEC99EN.html>

Date: April 2021

Pages: 52

Price: US\$ 125.00 (Single User License)

ID: UCCA23FEC99EN

## Abstracts

UniQure NV (QURE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## Highlights

UniQure NV (UniQure) develops and markets gene therapy products. The company develops adeno-associated virus (AAV) based gene therapies using its gene technology platform and offers disease-modifying treatments to patients with severe genetic diseases and other devastating diseases. UniQure's lead product, AMT-060 is a gene therapy for treatment of moderately-severe hemophilia B. Its preclinical products include AMT-130, an AAV5 vector for the treatment of Huntington's disease and AMT-150 for Spinocerebellar Ataxia type 3. The company develops a gene platform to bring new disease modifying therapies to patients with genetic diseases. The company conducts drug discovery and preclinical research in collaboration with academic research institutions. UniQure is headquartered in Amsterdam, North Holland, the Netherlands.

### UniQure NV Key Recent Developments

Mar 01, 2021: uniQure announces 2020 financial results and highlights recent company progress

Dec 02, 2020: uniQure to participate in multiple upcoming industry conferences in December

Oct 27, 2020: uniQure announces third quarter 2020 financial results and highlights recent company progress

Aug 26,2020: uniQure announces appointment of Ricardo Dolmetsch, Ph.D., as president, research & development

Jul 30,2020: uniQure announces second quarter 2020 financial results and highlights recent company progress

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

UniQure NV - Key Facts  
UniQure NV - Key Employees  
UniQure NV - Key Employee Biographies  
UniQure NV - Major Products and Services  
UniQure NV - History  
UniQure NV - Company Statement  
UniQure NV - Locations And Subsidiaries  
Head Office  
Other Locations & Subsidiaries

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
UniQure NV - Business Description  
Other Break-up: Collaboration Revenue  
Performance  
Other Break-up: License Revenue  
Performance  
R&D Overview  
UniQure NV - Corporate Strategy  
UniQure NV - SWOT Analysis  
SWOT Analysis - Overview  
UniQure NV - Strengths  
UniQure NV - Weaknesses  
UniQure NV - Opportunities  
UniQure NV - Threats  
UniQure NV - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios  
Financial Ratios - Annual Ratios  
Performance Chart  
Financial Performance  
Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

## **SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

UniQure NV, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

UniQure NV, Recent Deals Summary

## **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

Mar 01, 2021: uniQure announces 2020 financial results and highlights recent company progress

Dec 02, 2020: uniQure to participate in multiple upcoming industry conferences in December

Oct 27, 2020: uniQure announces third quarter 2020 financial results and highlights recent company progress

Aug 26, 2020: uniQure announces appointment of Ricardo Dolmetsch, Ph.D., as president, research & development

Jul 30, 2020: uniQure announces second quarter 2020 financial results and highlights recent company progress

Jun 17, 2020: uniQure announces the appointment of Leonard E. Post, Ph.D. to its Board of Directors

Apr 29, 2020: uniQure announces first quarter 2020 financial results and highlights recent company progress

Mar 03, 2020: uniQure to participate in multiple upcoming industry conferences in March

Mar 02, 2020: uniQure announces 2019 financial results and highlights recent company progress

## **SECTION 6 – APPENDIX**

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

UniQure NV, Key Facts  
UniQure NV, Key Employees  
UniQure NV, Key Employee Biographies  
UniQure NV, Major Products and Services  
UniQure NV, History  
UniQure NV, Subsidiaries  
UniQure NV, Key Competitors  
UniQure NV, Ratios based on current share price  
UniQure NV, Annual Ratios  
UniQure NV, Annual Ratios (Cont...1)  
UniQure NV, Interim Ratios  
UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
UniQure NV, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
UniQure NV, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios

## List Of Figures

### LIST OF FIGURES

UniQure NV, Performance Chart (2016 - 2020)

UniQure NV, Ratio Charts

UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

UniQure NV, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021



## I would like to order

Product name: UniQure NV (QURE) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/UCCA23FEC99EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/UCCA23FEC99EN.html>